At the Digital Life Global Recruitment Conference on January 5, 2017, Carbon Cloud Intelligence and seven ecosystem companies jointly launched a new digital health management platform, 觅 Me, from the founder and chairman of SomaLogic, Colorado, USA. Larry Gold presented the audience with their patented technology and related applications in proteomics testing. Due to the complexity of proteomic analysis technology, no company has developed corresponding detection methods so far, and SomaLogic has developed a breakthrough patent technology called SOMAscan, which can quantify protein, and it has also realized rapid detection technology. , large-scale and cost-effective, is unmatched by other companies in the world, and enables researchers from academia to the business community to measure proteins as easily as nucleic acids. In the future, SomaLogic will establish a joint venture with Carbon Cloud Intelligence in China to provide SOMAscan proteomics testing technology for China's research and health applications industry, while providing the basic protein information needed to build a digital life ecosystem. The following is a speech record:
Larry Gold (Founder and Chairman of SomaLogic): Hello everyone, I am very honored to be here today and become part of our vision. I will tell you what we have done. We are here to detect protein and use it as a way to understand the human body. A way of health. First of all, everyone has such a cognition that each of us has different lives and each person's world is different. Advances in science and technology have led humans to deepen their understanding of the composition of life, from the organizational level to the cellular level, to the molecular level, while interpreting life and improving human health.
The proteins that we study are very many in the human body, and some of them are very high in concentration and very low in some. These proteins reflect your real-time health: depending on your environment, the food you eat, and the medication you take, the protein in your blood changes in 2 hours. But so far, the method of detecting proteome has a problem: due to its high complexity and difficulty, it is currently not measured by efficient, accurate and fast techniques. Because this must be able to measure protein in the human body over time in different disease situations, we have a high-throughput, low-cost solution.
SOMAmer: The core technology of protein detection
In 2000, we established a proteome platform that can quickly detect changes in proteins. We developed a technology, SOMAmer: a slow rate modified protein aptamer, a new specific protein binder. This reagent can be combined with different proteins to detect proteins. We create synthetic nucleic acids that are not present in organisms and fold into unique configurations so that they can bind specifically to proteins intensively. In the past few years, we have done a lot of these things. We can now measure 5,000 of the 20,000 kinds of proteins in your body. This is our core technology. We put this technology in the carbon cloud. Intelligent platform for me, through cooperation to provide testing for Chinese users, we call it SOMAscan.
In the past 17 years, we have done research and exploration on many projects, and at the same time achieved good cost control. This is the real data we recorded. We followed a person for 4 years and digitized it by measuring the protein. For the proteins we measured, the 900 proteins in the central black part never changed, but some of the remaining proteins fluctuated up and down. Artificial intelligence is to analyze the proteins that fluctuate during these different periods, and their changes and the disease state of the individual. Association. That's why we work with Carbon Cloud to expand protein detection to millions of people. In the future, we will use artificial intelligence engines to drive these big data and make more customized products for individual health management.
Analysis and understanding of the data takes a lot of time. So far, we have measured 125,000 samples on SOMAscan. At the same time, we have also done a lot of research, mainly the analysis of some samples, including tissue, urine, blood and other samples, and we have carried out a variety of cancer and related research on diseases such as heart disease, variant disease and rare diseases. . Throughout the research process, we found that our future development prospects with Carbon Cloud, including our data, are very high.
CVD9: predicting the risk of heart disease recurrence
Here are two examples for you to briefly show how our research supports personalized medicine . There is a paper published last year, the first contributor is Dr. Peter Ganz, Department of Cardiology, San Francisco College, California. SomaLogic and Peter Peter worked together to conduct a small clinical trial of 1,000 people. The patients suffered from different levels of high-risk cardiovascular disease and received the same treatment in the United States with obvious efficacy. We underwent an eight-year follow-up. During the follow-up, we saw patients with similar cardiovascular disease, and the likelihood of a second episode was completely different. Some patients are no different from ordinary people after receiving treatment, and the other part is relatively risky. Therefore, we have studied a method to screen 9 blood proteins (CVD9) from 1130 proteins to help doctors identify which heart disease patients have a high risk of recurrence, so that these high-risk groups can receive appropriate treatment and get better. Efficacy.
360 Degree Ptz Camera,1080P Hd Camaras,Audio Wireless Wifi Camera,Hd Wifi Camera
Shenzhen Zuomi Technology Co., Ltd. , https://www.zuomicamera.com